September 24th 2021, 5:00pm
The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.
September 17th 2021, 12:20pm
A study of patients given first-line metastatic melanoma treatment showed that utilization rates were highest in patients using ipilimumab-containing therapies.
September 12th 2021, 1:00pm
This new analysis of combination treatment with ipilimumab and nivolumab identified factors likely to lead to therapeutic success with the combination.
September 10th 2021, 11:10am
Patients with BRAF-V600 mutated metastatic melanoma have new treatment options to consider, but scientists are still waiting on additional data to help choose which first-line treatments are best for which patients.
September 10th 2021, 11:00am
Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.
September 8th 2021, 7:00pm
Patients over the age of 65 had similar rates of serious adverse events, and nearly identical progression-free survival, when compared with younger patients.
September 5th 2021, 12:00pm
Being a full-service dermatology practice helps make patients' lives easier when they have skin cancer, explained Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.
August 31st 2021, 3:12pm
Results of a multicenter study showed 43% of patients with advanced melanoma treated with anti–programmed cell death 1 therapy experienced chronic complications.
August 25th 2021, 7:00pm
Autophagy inhibition could help patients who develop resistance to BRAF inhibitors, but a new review shows important questions remain.
August 22nd 2021, 3:30pm
Researchers outline factors that may inhibit immune checkpoint inhibitor efficacy in patients with melanoma.
.jpg?w=200&fit=crop&auto=format)
